JP2019512018A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512018A5
JP2019512018A5 JP2018560436A JP2018560436A JP2019512018A5 JP 2019512018 A5 JP2019512018 A5 JP 2019512018A5 JP 2018560436 A JP2018560436 A JP 2018560436A JP 2018560436 A JP2018560436 A JP 2018560436A JP 2019512018 A5 JP2019512018 A5 JP 2019512018A5
Authority
JP
Japan
Prior art keywords
hom
composition
tissue sample
expression
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018560436A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512018A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/015775 external-priority patent/WO2017136322A1/en
Publication of JP2019512018A publication Critical patent/JP2019512018A/ja
Publication of JP2019512018A5 publication Critical patent/JP2019512018A5/ja
Priority to JP2022143467A priority Critical patent/JP7635939B2/ja
Priority to JP2024153550A priority patent/JP2024170560A/ja
Pending legal-status Critical Current

Links

JP2018560436A 2016-02-04 2017-01-31 炎症性障害の治療及び診断 Pending JP2019512018A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022143467A JP7635939B2 (ja) 2016-02-04 2022-09-09 炎症性障害の治療及び診断
JP2024153550A JP2024170560A (ja) 2016-02-04 2024-09-06 炎症性障害の治療及び診断

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291271P 2016-02-04 2016-02-04
US62/291,271 2016-02-04
PCT/US2017/015775 WO2017136322A1 (en) 2016-02-04 2017-01-31 Treatment and diagnosis of inflammatory disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022143467A Division JP7635939B2 (ja) 2016-02-04 2022-09-09 炎症性障害の治療及び診断

Publications (2)

Publication Number Publication Date
JP2019512018A JP2019512018A (ja) 2019-05-09
JP2019512018A5 true JP2019512018A5 (enExample) 2020-03-12

Family

ID=59499992

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018560436A Pending JP2019512018A (ja) 2016-02-04 2017-01-31 炎症性障害の治療及び診断
JP2022143467A Active JP7635939B2 (ja) 2016-02-04 2022-09-09 炎症性障害の治療及び診断
JP2024153550A Pending JP2024170560A (ja) 2016-02-04 2024-09-06 炎症性障害の治療及び診断

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022143467A Active JP7635939B2 (ja) 2016-02-04 2022-09-09 炎症性障害の治療及び診断
JP2024153550A Pending JP2024170560A (ja) 2016-02-04 2024-09-06 炎症性障害の治療及び診断

Country Status (13)

Country Link
US (3) US11268095B2 (enExample)
EP (1) EP3411479A4 (enExample)
JP (3) JP2019512018A (enExample)
KR (1) KR20180109985A (enExample)
CN (1) CN108779461A (enExample)
AU (2) AU2017213744B2 (enExample)
CA (1) CA3013898A1 (enExample)
CL (3) CL2018002097A1 (enExample)
IL (2) IL311968A (enExample)
MX (2) MX2018009542A (enExample)
MY (2) MY203831A (enExample)
SG (2) SG11201806636SA (enExample)
WO (1) WO2017136322A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017213744B2 (en) 2016-02-04 2023-06-22 Hong Gao Treatment and diagnosis of inflammatory disorders
EP3952947A4 (en) 2019-04-11 2024-07-03 Enclear Therapies, Inc. METHODS FOR IMPROVING CSF AND DEVICES AND SYSTEMS THEREFOR
CN111528842B (zh) * 2020-05-26 2023-01-03 复嶂环洲生物科技(上海)有限公司 基于生理和行为指标的帕金森病症状定量化评估方法
AU2021355470A1 (en) 2020-09-29 2023-06-01 Enclear Therapies, Inc. Subarachnoid fluid management method and system
AU2022297513A1 (en) * 2021-06-23 2024-01-18 Enclear Therapies, Inc. Method of regulating gene expression

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2709309B1 (fr) 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
US5583153A (en) 1994-10-06 1996-12-10 Regents Of The University Of California Use of taxol in the treatment of rheumatoid arthritis
US20030035790A1 (en) 1999-01-15 2003-02-20 Shu-Hsia Chen Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
EP1222933A1 (en) 2001-01-15 2002-07-17 Academisch Ziekenhuis Leiden h.o.d.n., Leids Universitair Medisch Centrum Generation and/or reduction of new lung tissue in an affected lung, by modulation of the Wnt-pathway
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1592791A2 (en) 2003-02-10 2005-11-09 National Institute of Advanced Industrial Science and Technology Regulation of gene expression by dna interference
US20080248011A1 (en) 2004-01-27 2008-10-09 Medical And Biological Laboratories Co., Ltd. Methods for Isolating Monocytes
US20070248535A1 (en) 2005-02-07 2007-10-25 The Trustees Of Columbia University In The City Of New York Methods to treat or prevent hormone-resistant prostate cancer using siRNA specific for protocadherin-PC, or other inhibitors of protocadherin-PC expression or activity
WO2007051077A2 (en) 2005-10-28 2007-05-03 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
US20070161031A1 (en) 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
EP2021499A4 (en) 2005-12-16 2010-02-17 Univ Leland Stanford Junior FUNCTIONAL ARRAYS FOR THE IDENTIFICATION OF ELEMENTS FOR GENE PRESSION REGULATION WITH HIGH THROUGHPUT
US7994126B2 (en) 2006-02-22 2011-08-09 Zhenglun Zhu Treatment of cellular proliferative disorders with compositions comprising Hom polypeptide (also known as Xom, VENTX2)
EP2454372B1 (en) 2009-07-15 2018-10-03 Zhenglun Zhu Managing the treatment of inflammatory or autoimmune disorders using hom-1 expression
WO2012071513A2 (en) * 2010-11-24 2012-05-31 Hong Gao Expanding hematopoietic stem cells
WO2012170979A1 (en) * 2011-06-10 2012-12-13 Zhenglun Zhu Human homeobox gene ventx and macrophage terminal differentiation and activation, compositions and methods thereof
US20150297679A1 (en) 2012-12-14 2015-10-22 The Brigham And Women's Hospital, Inc. Methods and assays relating to macrophage differentiation
EP2984165B1 (en) * 2013-04-10 2020-12-23 Zhenglun Zhu Homeobox transcription factor ventx regulates differentiation and maturation of human dendritic cells
US9428748B2 (en) * 2013-06-17 2016-08-30 Hong Gao Method of expanding hematopoietic stem cells
CA2997912A1 (en) 2015-09-09 2017-03-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Genetic engineering of macrophages for immunotherapy
AU2016353064B2 (en) 2015-11-11 2022-12-22 Zhenglun Zhu Method of modifying macrophage differentiation and immunity
AU2017213744B2 (en) 2016-02-04 2023-06-22 Hong Gao Treatment and diagnosis of inflammatory disorders
EP3601539A4 (en) 2017-03-28 2021-01-13 Zhenglun Zhu METHODS OF TREATING NEOPLASIC DISEASES

Similar Documents

Publication Publication Date Title
JP2019512018A5 (enExample)
Denby et al. MicroRNA-214 antagonism protects against renal fibrosis
Zhang et al. MicroRNA-155 contributes to preeclampsia by down-regulating CYR61
Liu et al. LncRNA MALAT1/MiR-145 adjusts IL-1β-induced chondrocytes viability and cartilage matrix degradation by regulating ADAMTS5 in human osteoarthritis
Manoury et al. TIMP-1 is a key factor of fibrogenic response to bleomycin in mouse lung
US11053314B2 (en) Methods to eliminate cancer stem cells by targeting CD47
Witalison et al. Molecular targeting of protein arginine deiminases to suppress colitis and prevent colon cancer
ES2724549T3 (es) ARN pequeños derivados de RNY como biomarcadores para trastornos relacionados con la aterosclerosis
Ni et al. CircSLC7A2 protects against osteoarthritis through inhibition of the miR‐4498/TIMP3 axis
US20180110837A1 (en) Methods and assays relating to macrophage differentiation
Litwin et al. Gelsolin affects the migratory ability of human colon adenocarcinoma and melanoma cells
Shiba et al. Differential roles of MMP-9 in early and late stages of dystrophic muscles in a mouse model of Duchenne muscular dystrophy
WO2021231887A1 (en) Compositions and methods of detection of pre-symptomatic als
WO2019229259A1 (en) Materials and methods for monitoring the development of resistance of cancers to treatment
CN105987999A (zh) 用于乳腺癌诊断的联合肿瘤标志物及其试剂盒
Tan et al. Circular RNA XRCC5 aggravates glioma progression by activating CLC3/SGK1 axis via recruiting IGF2BP2
CN114901835B (zh) 包含mir-335的组合物
TW202402790A (zh) 減少呼吸系統感染之方法
Yang et al. CircITGA7 regulates malignant phenotypes in bladder cancer cells via targeting miR‐330‐3p/KLF10 axis
CN116270710B (zh) circRBM33作为靶点在前列腺癌诊断和治疗中的应用
Kum et al. Antifibrotic effect via the regulation of transcription factor Sp1 in lung fibrosis
Ma et al. MMP19 in vascular smooth muscle cells protects against thoracic aortic aneurysm and dissection via the MMP19/Aggrecan/Wnt/β-catenin axis
Xin et al. Upregulation of MiR-29b contributes to mesenchymal stem cell dysfunction in patients with severe pre-eclampsia
US20160138026A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF VprBP-RELATED CANCERS
US20220307030A1 (en) Uses of synthetic lethal partners for treatment of cancer